Novo Nordisk gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat
After abruptly shutting down three hemophilia studies back in March due to serious safety issues, Novo Nordisk is getting things going again.
The Danish pharma gave the go-ahead to resume Phase III trials for its concizumab candidate, which are investigating subcutaneous prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status. Novo Nordisk had halted the studies after three patients experienced non-fatal blood clots.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.